Two Merck Medicines Recommended For Approval In The European Union
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE™
FDA Provides Clarity To Isis Regarding The Development Path For Mipomersen
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).
Higher Cholesterol Increases Risk Of Boichemical Failure After Radical Prostatectomy
Poor cholesterol management may not only affect a man's risk for prostate cancer, but also his risk of biomedical recurrence after prostatectomy, according to new data from Duke University.
Analysis: Control Reduces Cardiovascular Risk By 42
Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure was less than 140 mmHg reduced the risk of major cardiovascular events, including heart attack, stroke and resuscitated cardiac arrest, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher.
CocoaVia Dark Chocolate Bars Shown To Lower Cholesterol
The results of a University of Illinois study have demonstrated an effective way to lower cholesterol levels - by eating chocolate bars."Eating two CocoaVia dark chocolate bars a day not only lowered cholesterol, it had the unexpected effect of also lowering systolic blood pressure, " said John Erdman, a U.
Physicians And Patients Nationwide Discuss Controversial Results Of Recent Cholesterol Lowering Study
Sermo (http://www.sermo.com), the largest physician-only online community, today announced the results of a physician survey prompted by the swirl of media coverage following the release of ENHANCE trial data at the recent American College of Cardiology (ACC) conference.
Sorting Of CEA Modulated By Cholesterol, Implications For Inflammatory Bowel Disease
In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface. Interestingly, polarity was not significantly affected by this approach.
eFoodSafety Launches Cinnechol TM , An All-Natural Alternative To Conventional Cholesterol Drugs
eFoodSafety.com (OTCBB: EFSF, http://www.efoodsafety.com), a researcher, developer, and marketer of whole food nutraceutical products, has launched an all-natural supplement, called Cinnechol™ (http://www.cinnechol.com), that offers a complementary and/or alternative solution to traditional cholesterol drugs.
Cholesterol, Blood Pressure Control May Reverse Atherosclerosis In Adults With Diabetes
Aggressively lowering cholesterol and blood pressure levels below current targets in adults with type 2 diabetes may help to prevent - and possibly reverse - hardening of the arteries, according to new research supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Merck Receives Not Approvable Letter From FDA For MK-0524A ER Niacin laropiprant
Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia.